Inhibin as a diagnostic marker for ovarian cancer

Abstract The inhibins are a family of growth factors comprised of several different species that are secreted in the female principally from the ovarian follicle. The inhibins perform best as markers of ovarian cancer when measured collectively (total inhibin) by immunoassays targeted to common epit...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters 2007-04, Vol.249 (1), p.14-17
Main Authors: Robertson, David M, Pruysers, Enid, Jobling, Tom
Format: Article
Language:English
Subjects:
Biomarkers, Tumor - blood
CA125
Female
Granulosa cell tumour
Hematology, Oncology and Palliative Medicine
Humans
Inhibin ELISA
Inhibins - blood
Menopause
Menstruation
Molecular weight
Mucinous tumours
Ovarian cancer
Ovarian Neoplasms - blood
Ovarian Neoplasms - diagnosis
Studies
Tumors
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The inhibins are a family of growth factors comprised of several different species that are secreted in the female principally from the ovarian follicle. The inhibins perform best as markers of ovarian cancer when measured collectively (total inhibin) by immunoassays targeted to common epitopes. After menopause with the depletion of ovarian follicles, the circulating level of total inhibin becomes undetectable. In contrast, serum total inhibin levels are elevated in women with ovarian cancer, in particular those with granulosa cell tumours and those with the mucinous subtype of epithelial carcinoma. Investigations into the clinical utility of inhibin to detect ovarian cancer have shown that it complements CA125, an established marker of epithelial ovarian cancer, in that each performs best in detecting different subtypes of ovarian cancer. In some published studies, the two markers together have detected up to 95% of ovarian cancers with 95% specificity.
ISSN:0304-3835
1872-7980
DOI:10.1016/j.canlet.2006.12.017